Gmax Biopharm Funding: $78M Raised, Series C (2021)

Gmax Biopharm is based in Hangzhou, China. It has raised $78M in total funding. Latest round: Series C.

Gmax Biopharm funding overview

Gmax Biopharm is based in Hangzhou, China. Gmax Biopharm has raised $78M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in March 2021. The round record for Gmax Biopharm runs through 2021; nothing later has been disclosed. Investors on record include China Merchants Group, Tigermed, Parkland Medtech Limited, Cowin Capital, Ziyao Fund. 5 distinct backers are named across the disclosed rounds.

Gmax Biopharm at a glance

Total raised
$78M
Latest round
Series C
Latest round date
March 2021
Headquarters
Hangzhou, China
Notable investors
China Merchants Group, Tigermed, Parkland Medtech Limited, Cowin Capital, Ziyao Fund

Frequently asked about Gmax Biopharm funding

How much has Gmax Biopharm raised?
Gmax Biopharm has raised $78M in total disclosed funding across the rounds on record.
Who has invested in Gmax Biopharm?
China Merchants Group, Tigermed, Parkland Medtech Limited, Cowin Capital, Ziyao Fund are named among the investors backing Gmax Biopharm.
What was the latest Gmax Biopharm funding round?
The most recent disclosed round is a Series C, announced in March 2021.
Where is Gmax Biopharm based?
Gmax Biopharm is based in Hangzhou, China.
When did Gmax Biopharm last raise?
The last disclosed Gmax Biopharm round closed in March 2021 at Series C.

Round data for Gmax Biopharm is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Hangzhou and backer lists below.

Companies related to Gmax Biopharm (21)

Browse related funding lists (4)

Company funding database · Investor directory · Founder database · Mega-rounds 2026